Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more
Market Cap & Net Worth: Belite Bio, Inc (D01)
Belite Bio, Inc (F:D01) has a market capitalization of $5.35 Billion (€5.21 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #4596 globally and #453 in its home market, demonstrating a -9.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Belite Bio, Inc's stock price €139.00 by its total outstanding shares 37514630 (37.51 Million).
Belite Bio, Inc Market Cap History: 2026 to 2026
Belite Bio, Inc's market capitalization history from 2026 to 2026. Data shows growth from $5.35 Billion to $5.35 Billion (0.00% CAGR).
Belite Bio, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Belite Bio, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of D01 by Market Capitalization
Companies near Belite Bio, Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Belite Bio, Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Belite Bio, Inc Historical Marketcap From 2026 to 2026
Between 2026 and today, Belite Bio, Inc's market cap moved from $5.35 Billion to $ 5.35 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Belite Bio, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.35 Billion USD |
| MoneyControl | $5.35 Billion USD |
| MarketWatch | $5.35 Billion USD |
| marketcap.company | $5.35 Billion USD |
| Reuters | $5.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.